Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.61+5.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GALT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 8.9 | 14.3 | 36.6 | 32.1 | 31.7 | 23.8 | 18.0 | 7.5 | 6.5 | 11.7 | 15.3 | 13.1 | 8.4 | 5.7 | 4.5 | 3.6 |
| Operating Income | (15.6) | (20.1) | (42.4) | (38.1) | (38.4) | (30.2) | (23.4) | (13.4) | (13.6) | (16.2) | (21.5) | (20.1) | (15.4) | (12.1) | (9.9) | (10.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 7.3 | 5.5 | 2.8 | 1.0 | 0.5 | 0.1 | 0.1 | 0.3 | 0.0 | — | — | — | — | — | — |
| Interest & Investment Income | 0.1 | 0.1 | 0.3 | 0.2 | 0.1 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | 2.6 | 1.0 | 0.5 | 0.0 | (0.1) | 0.3 | (0.0) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (12.2) | (10.8) | (4.6) | (3.0) | (0.4) | (0.3) | (0.0) | 0.1 | (0.3) | 0.0 | 0.0 | 0.1 | (0.4) | 0.0 | 0.2 | (0.5) |
| Net Income | ||||||||||||||||
| Net Income | (27.8) | (30.8) | (47.0) | (41.1) | (38.8) | (30.5) | (23.5) | (13.3) | (13.9) | (16.2) | (21.4) | (20.0) | (15.8) | (12.1) | (9.7) | (10.9) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.42) | (0.48) | (0.76) | (0.74) | (0.65) | (0.52) | (0.41) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.42) | (0.48) | (0.76) | (0.74) | (0.65) | (0.52) | (0.41) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 65.9 | 63.9 | 62.3 | 60.2 | 59.4 | 58.5 | 57.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 65.9 | 63.9 | 62.3 | 60.2 | 59.4 | 58.5 | 57.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | (42.4) | (38.1) | (38.4) | (30.2) | (23.4) | (13.4) | (13.6) | (16.2) | (21.5) | (20.1) | (15.4) | (12.1) | (9.9) | (10.4) |
| EBIT | (15.6) | (20.1) | (42.4) | (38.1) | (38.4) | (30.2) | (23.4) | (13.4) | (13.6) | (16.2) | (21.5) | (20.1) | (15.4) | (12.1) | (9.9) | (10.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.